It was at a singular moment when his illness echoed the global pandemic of COVID-19 that Dr. Tomisaku Kawasaki ([Fig. 1](#fig0005){ref-type="fig"} ) left us discreetly at the age of 95 from his hometown of Tokyo. Dr. Kawasaki studied medicine at Chiba university in Tokyo and then specialized in pediatrics at the Red Cross Medical Centre where he later became head of the department. In 1961, he saw for the first time in a 4-year-old boy with a 2-week fever, a singular association of clinical signs. Indeed, the boy presented with non-purulent conjunctivitis, red, dry, and fissured lips, a raspberry tongue, bulky cervical lymphadenopathy, erythema multiforme, and changes in the extremities (redness, swelling of the palms and soles) [@bib0005]. Since then, Tomisaku Kawasaki was convinced that it was a new disease. However, during his various presentations of the case at pediatric congresses at Chiba and in Tokyo, he received frank opposition from his peers, who considered at that time that he was not describing anything new other than Still\'s disease or erythema multiforme. In the following years between 1961 and 1967, he reported 50 additional cases in a 44-page manuscript regularly cited and that remains exceptional in its descriptive and illustrative quality. At that time, however, the cardiac signs were unknown and it was not until 1970 that a Japanese epidemiological study mentioned 10 deceased patients at whose autopsy aneurysms and coronary thromboses were found [@bib0010], [@bib0015]. *Nelson\'s Textbook of Pediatrics* first cited this entity as "mucocutaneous lymph node syndrome" or "Kawasaki disease" in 1978 [@bib0015]. While cardiac ultrasound was still in its infancy in 1970, the first angiograms performed by his friend Prof. Hirohisa Kato showed that aneurysms could be present even in asymptomatic subjects [@bib0010]. A "little story" by Dr. Jane Burns in San Diego tells us, however, that the first case of Kawasaki disease possibly occurred in 1950 in a Japanese patient who had had mumps twice. She had the opportunity to meet him at the age of 48 in San Diego when he had a massive heart attack due to a thrombosis in a giant aneurysm [@bib0020]. Dr. Kawasaki has received numerous distinctions in Japan and the United States. He created and became the director the Japanese Research Center for Kawasaki Disease. He has given numerous lectures in Asia and the United States, which sometimes ended with "standing ovations". He regularly attended conferences bearing his name, until 2015 in Honolulu. He always made a short speech there, accompanied by his wife, and posed happily in photo sessions, which for all of us represented a strong and solemn moment during these events.Fig. 1Portrait of Dr. Tomisaku Kawasaki. Personal collection of Isabelle Koné-Paut.

Kawasaki disease has now spread worldwide, and although its incidence remains prevalent in Asia and Hawaii, it is increasing in all countries. His clinical diagnosis, even enriched by cardiac complications, still fits faithfully with the description that Tomisaku Kawasaki made, but it remains difficult to confirm it early in the course of the disease because of the frequency of incomplete and atypical presentations. Demonstrating the effectiveness of intravenous immunoglobulins in reducing the incidence of heart complications from 25% to 5% has been a significant therapeutic advance for the vast majority of patients.

However, more than 60 years from its initial description, the etiology remains unclear, even if all data indicated that the hyper inflammatory phenotype occurs in individuals genetically predisposed secondarily to exposure to a pathogen (or other stress signal). Genetic susceptibility to Kawasaki disease strongly involves genes associated with the innate immune response. The increased intestinal permeability of IgA could play a critical role in the development of coronary lesions because they are present in abundance in endothelial cell injury.

The COVID-19 pandemic, which also started in Asia, arrived in a highly unexpected way, appropriate or not, to show us the complexity of defining cases of Kawasaki disease. Indeed, the now well-known pediatric inflammatory multi-system syndrome (PIMS) has made it even more evident that Kawasaki disease may be a syndrome overlapping with other hyper-inflammatory states including a cytokine storm such as in Still\'s disease and macrophage activation syndrome, among others [@bib0025]. This coincidental conjunction will allow for a greatly improved understanding of its pathophysiology and will help advance its therapeutic management.

Tomisaku Kawasaki was a sharp-eyed and sympathetic pediatrician who had never been much talked about, but continues to bring together pediatricians of all specialties. We owe him a tribute, to which we have added a few testimonies from his colleagues and friends: previously published or collected for this occasion.

Professor Hirohisa Kato (Kurume, Japan): "He is an astute clinician and has the knack of making precise and detailed clinical observations and meticulously recording them. He is very friendly and warm and loves interacting with young children and their parents" [@bib0015].

Doctor Jane Burns (San Diego, USA): "Dr. K inspired a generation of international researchers and clinicians to tackle the mysteries of the disease that bears his name. He taught us that keen observation and persistence were all that was necessary to describe a new disease."

Professor Rolando Cimaz (Milan, Italy): "Dr Tomisaku Kawasaki was a legend for all people who were interested in the disease that bears his name. He was always present at the international meetings, happy to take photos as a celebrity! His wife was always at his side in his last years, when he was wheelchair bound, but they were happy to raise a toast and drink a glass of wine to celebrate. He will be remembered by many".

Doctor Moshe Arditi (Los Angeles, USA): "Dr. Kawasaki always said to his students: 'Be strict and sincere to medicine, be kind and heartwarming to your patients, reading textbooks and papers is important, but seeing a patient is much more important'."

Thank you and rest in peace!
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